Features You Can Count On

Features of RhoGAM include:

  • RhoGAM comes in a pre-filled, ready-to-use syringe that eliminates the need for preparation steps1
  • Syringe provided with a 22-gauge, 1 ¼” needle2
  • Safety Shield was designed to offer protection from needlesticks by completely encompassing the needle once engaged1
  • Administration right out of the refrigerator - there are no temperature restrictions
    associated with administration1
  • ~1 mL fill volume2*
  • No light protection required1

* 0.5- to 1.2-mL range. Each single dose prefilled syringe contains 300 μg (1500 IU) of Rho(D) Immune Globulin (Human)

Please note, RhoGAM is intended for maternal use only and should not be administered to the newborn infant.

1. RhoGAM Ultra-Filtered PLUS Prescribing Information, 2015. Kedrion Biopharma Inc.
2. Data on file. Kedrion Biopharma Inc. 


Important Safety Information

RhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (300 μg) and MICRhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (50 μg) are indicated for the prevention of Rh immunization, including during and after pregnancy and other obstetrical conditions or incompatible transfusion of Rh-positive blood.

RhoGAM® and MICRhoGAM® are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent.

RhoGAM® and MICRhoGAM® are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration.

RhoGAM® and MICRhoGAM® contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. Patients who receive RhoGAM® and MICRhoGAM® for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.

You are encouraged to report adverse events of prescription drugs to the FDA.
Visit www.fda.gov/Safety/MedWatch/ or call 1-800-FDA-1088.

Click here for the RhoGAM Full Prescribing Information

This site is intended for residents of the US only.


Back to top